The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara® (ustekinumab)...
Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech’s footprint in the UKBioNTech...
LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Live video webcast on Wednesday, January 18th at 11:00 AM ETOCALA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data expected in 2H 2023Second-generation...
Co-development of 3D Vision System Solutions to Facilitate Rapid Development and Fast Time-to-Market of New ProductsLAS VEGAS , Jan. 05,...
POSH-MAP and PORT-MAP investigator-sponsored trials to evaluate ability of ACER-801 (osanetant) to reduce hot flashes and as neoadjuvant therapy in...
Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation and Global Drug ApprovalsNEW YORK,...
-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults...
– Final cohort of Phase 1 study projected to be complete in H1 2023 – – Phase 2-enabling GLP toxicology...
Company preliminarily reports nine Focal One Placements in the U.S., including seven sales LYON, France, January 5, 2023 -- EDAP...
6th Sachs Annual Neuroscience Innovation Forum12th Annual LifeSci Advisors Corporate Access Event41st Annual J.P. Morgan Healthcare ConferenceInvest Securities Biomed Forum...
AUM302 is potentially eligible to receive a rare pediatric disease priority review voucher at the time of marketing approvalSINGAPORE and...
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...
Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and...
Positive and clinically meaningful pivotal clinical results announced in 2022 in both metastatic and locally advanced indicationsWALTHAM, Mass., Jan. 04,...
REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming...
CBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy targetSAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc....
MORRISVILLE, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,...
– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million – – Adjusted Operating Expenses* Expected...